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I M M U N O L O G Y
Remodeling of metabolism and inflammation by 
exercise ameliorates tumor-associated anemia
Regula Furrer1, Annaïse J. Jauch2, Tata Nageswara Rao3†‡, Sedat Dilbaz1, Peter Rhein4,  
Stefan A. Steurer1, Mike Recher2, Radek C. Skoda3, Christoph Handschin1*
A considerable number of patients with cancer suffer from anemia, which has detrimental effects on quality of life 
and survival. The mechanisms underlying tumor-associated anemia are multifactorial and poorly understood. 
Therefore, we aimed at systematically assessing the patho-etiology of tumor-associated anemia in mice. We 
demonstrate that reduced red blood cell (RBC) survival rather than altered erythropoiesis is driving the development 
of anemia. The tumor-induced inflammatory and metabolic remodeling affect RBC integrity and augment splenic 
phagocyte activity promoting erythrophagocytosis. Exercise training normalizes these tumor-associated abnormal 
metabolic profiles and inflammation and thereby ameliorates anemia, in part, by promoting RBC survival. Fatigue 
was prevented in exercising tumor-bearing mice. Thus, exercise has the unique potential to substantially modulate 
metabolism and inflammation and thereby counteracts pathological remodeling of these parameters by the 
tumor microenvironment. Translation of this finding to patients with cancer could have a major impact on quality 
of life and potentially survival.
INTRODUCTION
Cancer is the second leading cause of death worldwide and, according 
to the World Health Organization, is responsible for nearly 10 million 
deaths per year. Besides cachexia, anemia is one of the most fre-
quently reported complications of cancer. Approximately one-third 
of newly diagnosed patients with cancer suffer from anemia before 
any treatment (1, 2). Most of these patients have mild anemia, but 
even such low pretreatment hemoglobin (Hb) levels are associated 
with reduced survival (2, 3). Moreover, in response to tumor-reductive 
therapy, 75% of patients will develop anemia (1). Cancer-related 
anemia is associated with fatigue and a substantial reduction in 
quality of life (4, 5) and is an independent predictor for survival (6). 
The current standard care for anemic patients with cancer exclusively 
focuses on augmenting erythropoiesis and is limited to iron supple-
mentation, erythropoiesis-stimulating agents such as erythropoietin 
(EPO), or blood transfusion for patients suffering from severe anemia 
(7). However, treating cancer patients with recombinant EPO re-
mains controversial as malignant cells express EPO receptors, and 
the treatment is even associated with increased mortality (8, 9). 
Notably, however, the causes of cancer-related anemia are multifac-
torial and can include blood loss, reduced intake or absorbance of 
nutrients, and suppression of hematopoiesis by malignant bone 
marrow infiltration or radio-/chemotherapy (10). Furthermore, sys-
temic effects of cancer, such as elevated cytokines levels, could also 
promote the development of anemia synergizing with direct conse-
quences of tumor load or treatment modalities (7). Accordingly, 
plasma levels of the proinflammatory cytokines interleukin-1 (IL-1), 
IL-6, and tumor necrosis factor– (TNF) are negatively correlated 
with Hb levels in patients with cancer (11). In addition to patients 
with cancer, anemia is often observed in patients with chronic in-
flammatory diseases such as congestive heart failure or chronic 
pulmonary or kidney diseases (7). The inflammatory environment 
might promote anemia in a pleiotropic manner, although causality 
is ill-defined. For example, compared to patients suffering from 
iron deficiency anemia without malignancy who have highly elevated 
EPO levels, in anemic patients with cancer, EPO production is 
blunted (12). This is potentially mediated by circulating cytokines, 
with likely implications on erythropoiesis (13). Red blood cell 
(RBC) production could further be dysregulated by impaired iron 
utilization because of IL-6–stimulated hepcidin production in the 
liver, thereby reducing iron availability for erythropoiesis (14). 
Curiously, however, administration of very high doses of IL-6 (i.e., 
1 mg/kg) boosts medullary and extramedullary erythropoiesis (15). 
In contrast, injecting high doses of IL-1 or TNF suppresses matu-
ration of erythroid progenitors (16, 17). Thus, although an associa-
tion between inflammation and the production of RBCs has been 
postulated, most studies are correlative or used high doses of the 
candidate cytokines.
In addition to the impaired production, RBC survival is also 
reduced in patients with conditions associated with high levels of 
inflammation such as rheumatoid arthritis or chronic diseases 
(18, 19). This suggests that proinflammatory cytokines could also 
reduce RBC half-life (20). RBC life span in tumor-bearing (TB) 
mice seems to be decreased because of elevated apoptosis of erythro-
cytes, so-called eryptosis (21), which also has been reported in 
anemic patients with cancer (22). However, most assumptions are 
based on correlations, and it remains elusive which factors alter 
RBC survival and could thereby be involved in the development of 
tumor-associated anemia. Notably, in addition to cytokines, many 
other substances (i.e., oxysterols and reactive oxygen species) 
and stressors (i.e., glucose starvation) inducing distinct metabolic 
responses in RBCs have been shown to promote eryptosis (23–26). 
It is conceivable that the tumor-induced systemic remodeling 
alters the RBC niche that is crucial for its survival. Hence, the 
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underlying mechanisms of tumor-associated anemia are still poorly 
understood.
In summary, despite the large number of patients with cancer 
suffering from anemia and the marked detrimental effects of anemia 
on quality of life and survival, there is still a lack of knowledge on 
the pathophysiology of tumor-associated anemia, leading to an in-
sufficient portfolio of treatment avenues. Consequently, it is instru-
mental to obtain a better understanding of the mechanistic aspects 
related to RBC production, maturation, and elimination in this dis-
ease context. Because of the limited possibilities to analyze the 
different facets of anemia in patients with cancer, we used a mouse 
tumor model that develops robust anemia and recapitulates patho-
logical key features observed in patients with cancer (27). This allows 
a thorough dissection of the effects of tumor growth on different 
organs and on systemic remodeling. Our study revealed that tumor- 
associated anemia was mainly caused by reduced RBC survival, 
without impairments in erythropoiesis. We provide solid evidence 
that the tumor-induced metabolic and immune dysregulation 
accentuated RBC fragility and made them more susceptible for 
phagocyte-mediated elimination. We lastly used exercise as a po-
tential intervention, since training-based therapies are currently 
being tested to mitigate cachexia, the other most common cancer 
complication besides anemia. Therapeutically, we demonstrate that 
endurance training markedly normalized the RBC environment, 
thereby attenuated the development of anemia and improved per-
formance, all of which could have meaningful implications for the 
treatment of patients with cancer.
RESULTS
Tumors lead to reduced RBC survival rather than  
impaired erythropoiesis
To investigate the systemic alterations responsible for the anemia 
caused by the tumor rather than metastasis, blood loss, or chemo-
therapy, we used a well-established primary cancer model and in-
jected Lewis lung cancer (LLC) cells subcutaneously into the flank 
of C57BL/6J mice. LLC tumors (weighing 1005 ± 284 mg after 
3.5 weeks; n = 6) induce severe anemia within 3.5 weeks, reaching 
Hb levels below 5 g/dl (Fig. 1A). To analyze whether this substantial 
drop in Hb was caused by reduced erythropoiesis, Ter119+ erythroid 
cells were assessed in bone marrow and the spleen. In stark contrast 
to the remarkable anemia in the periphery, erythropoiesis was not 
impaired in TB mice but was even increased as reflected by the 
higher percentage of Ter119+ cells in the spleen (Fig. 1B). This 
erythropoietic potential of the spleen in TB mice is also demonstrated 
by the threefold elevation in the relative number of CD71+ erythroid 
precursors and the massive induction of mRNA expression of genes 
involved in erythropoiesis and heme synthesis (Fig. 1C). Gene 
expression was measured in whole-tissue homogenate of the spleen 
and therefore includes changes in the cell population of the spleen. 
In line with these results, we observed a relative augmentation of the 
premature stages II, III, and IV in Ter119+ bone marrow and spleen 
cells in TB compared to healthy control (Ctrl) mice, whereas fully 
mature stage V RBCs were relatively reduced (Fig. 1, D and E). This 
suggests that there is an accelerated release of premature RBCs to 
meet the elevated demand. Accordingly, there was a higher percentage 
of premature stage IV and a decrease in stage V RBCs in the blood 
of TB as compared to Ctrl animals (Fig. 1F). These observations 
were further substantiated by assessing the abundance of CD71 and 
DNA content by DRAQ5 in Ter119+ cells (fig. S1). Similar to the 
CD44+ cells, the relative amount of CD71+Ter119+ cells was consid-
erably elevated, indicating a higher number of premature RBCs in 
TB mice (fig. S1A). The absence of DRAQ5 in these CD71+Ter119+ 
cells suggests that these are reticulocytes and already expelled their 
nucleus (fig. S1B). These findings are also reflected in the larger 
RBCs of TB mice (Fig. 1G). Together, these data imply that rather 
than impaired, erythropoiesis is massively increased in TB mice 
and does therefore not provide an adequate explanation for the 
observed anemia.
Next, we tested whether the removal of RBCs is elevated in TB 
animals and could contribute to the severe reduction in Hb. To 
measure RBC removal/survival, mice were injected with sulfo–N- 
hydroxysuccinimide (NHS)–Biotin intravenously before tumor ini-
tiation and biotinylated Ter119+ RBCs were analyzed longitudinally 
in peripheral blood. Mirroring anemia, RBC elimination was accel-
erated in TB mice throughout tumor development (Fig. 2A). Thus, 
to investigate whether RBCs of TB mice are more stressed and show 
abnormalities, we assessed phosphatidylserine externalization, a cel-
lular marker of enhanced eryptosis. In TB mice, a fivefold increase 
in the number of phosphatidylserine-exposing RBCs was found as 
measured by annexin V binding (Fig. 2B), implying an inherent 
predisposition for phagocytosis. As the spleen is the main organ for 
RBC removal (28), the massive splenomegaly in TB mice (Fig. 2C) 
could be instrumental for the compromised RBC survival. To gain 
insight into the origin of this splenomegaly, we assessed the cell 
composition of spleens of Ctrl and TB mice. Notably, the number of 
CD45+ cells was markedly reduced to approximately one-third of 
that of a Ctrl spleen (Fig. 2D). However, when calculating the total 
number of CD45+ cells per spleen, this difference disappeared when 
taking into account the spleen mass and number of cells, indicating 
that the enlargement of the spleen is not caused by leukocyte expan-
sion. Within the CD45+ population, lymphoid cell numbers were 
similar between Ctrl and TB mice, with only a slight reduction in 
the relative amount of T cells in TB animals (Fig. 2E). The main 
changes occurred in myeloid cells, which were more abundant be-
cause of a relative increase in F4/80high macrophages and CD11bhigh 
monocytes/neutrophils in TB compared to Ctrl mice. Of the CD45− 
splenocytes, more than 50% were CD71+ in TB mice, while in a 
healthy spleen, less than 10% of splenocytes are CD71+ (Fig. 2F). 
Our data demonstrate that the splenomegaly in TB mice is not the 
result of leukocyte expansion but rather the consequence of increased 
extramedullary erythropoiesis reflected by the high number of 
CD71+ erythroid precursors and the elevated transcription of genes 
involved in erythropoiesis (Fig. 1C).
To investigate whether splenic RBC elimination is enhanced in 
TB mice, we performed an in vitro erythrophagocytosis assay. Spleno-
cytes were isolated from Ctrl and TB animals and coincubated with 
PKH26 fluorescently labeled healthy Ctrl RBCs. After 1 hour, RBCs 
were lysed and splenocytes were analyzed by flow cytometry. Next, 
we used ImageStream® to visualize PKH26+ phagocytes. The gates 
were set according to the fluorescence of the PKH26-labeled RBC 
(Fig. 3, A and B). More specifically, PKH26med phagocytes showed 
the same intensity as PKH26-labeled RBC, while PKH26high phago-
cytes have a higher fluorescent signal. First, we determined whether 
the RBCs were internalized by the phagocytes by determining the 
internalization score and observed that only PKH26high phagocytes 
showed complete internalization of the RBCs with a score above 0 
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Fig. 1. Tumor-associated anemia is accompanied by augmentation of extramedullary erythropoiesis. Tumor was induced by injecting LLC cells into the flank of mice. 
(A) Time course of Hb levels in Ctrl and TB mice throughout the study. (B) Ter119+ erythroid cells were assessed in the bone marrow and spleen by flow cytometry. (C) CD71+ cells 
within the Ter119+ population were determined, and mRNA levels of gene involved in erythropoiesis and heme synthesis were measured in whole-spleen homogenate by semi 
quantitative polymerase chain reaction (qPCR). (D to F) Maturation of Ter119+ cells were analyzed according to their size and CD44 expression in the bone marrow (D), spleen (E), and 
blood (F) as shown in the representative flow cytometry plots and quantified in the bar graphs. (G) RBC size was assessed during the blood count using Advia 2021 (mean 
corpuscular volume). Groups (n = 6 per group) were compared by two-tailed unpaired t tests with Welch’s correction, and data are represented as means + SEM. Asterisks indicate 
differences between Ctrl and TB group. *P < 0.05, **P < 0.01, and ***P < 0.001. Kilt/SCF, kit ligand/stem cell factor; Tfrc/CD71, transferrin receptor; Gata1, GATA binding 
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revealed that PKH26med phagocytes predominantly contain PKH26+ 
fragments (Fig. 3D and fig. S2B), which could be the result of small 
vesicles originating form phosphatidylserine-positive RBCs (29). 
In contrast to the fragments observed in PKH26med phagocytes, 
PKH26high phagocytes engulfed the entire RBCs (Fig. 3D and fig. 
S2B). Therefore, we determined the relative amount of PKH26high 
F4/80highCD11blow red pulp macrophages (RPMs), F4/80highCD11bhigh 
macrophages, and F4/80lowCD11bhigh monocytes/neutrophils 
(Fig. 3, E  to G). Notably, the percentage of highly fluorescent 
F4/80highCD11blow RPMs and F4/80highCD11bhigh macrophages were 
elevated in TB compared to Ctrl mice (Fig. 3, F and G). Considering 
the higher abundance of macrophages in TB mice combined with 
the boosted phagocytic activity of these macrophages to remove 
RBCs, we provide evidence for the tremendous potential of the 
spleen of TB mice for erythrophagocytosis.
Together, our results reveal that splenic macrophages of TB mice 
are more activated and phagocytose a higher number of healthy 
RBCs. Subsequently, we were interested whether RBCs of TB 
animals are also more susceptible to be removed by macrophages. 
To test this, we cocultured splenocytes of healthy Ctrl mice with 
PKH26-labeled RBCs from Ctrl versus TB animals. A particular cell 
population showed enhanced removal of RBCs from TB mice. More 
specifically, a higher percentage of F4/80lowCD11bhigh monocytes/
neutrophils were PKH26high (Fig. 3, H and I), which is in line 
with previous reports showing that neutrophils specifically increase 
erythrophagocytosis of stressed RBCs (30). We made an intriguing 
observation regarding differences in RBC morphology between Ctrl 
and TB mice (fig. S2, C and D). A larger proportion of RBCs of TB 
mice showed a stomatocyte-like morphology, while the population 
displaying healthy discocyte-like morphology was reduced. This 
RBC abnormality is also seen in RBCs of long-stored blood and is 
linked to an elevated susceptibility for phagocyte-mediated removal 
(31). In summary, splenic macrophages are activated in TB animals 
and show an elevated activation to remove RBCs from the circula-
tion. In addition, RBCs of TB mice show abnormalities reflected by 
the increased phosphatidylserine exposure and altered morphology 
and are therefore more susceptible to be eliminated by phagocytes. 
Collectively, these tumor-induced alterations result in a reduced 
RBC survival, which subsequently contributes to the development 
of tumor-associated anemia.
An altered metabolic and immune profile negatively 
affects RBC survival
To investigate how the tumor contributes to RBC abnormalities such 
as phosphatidylserine externalization, systemic factors that could 
affect the RBC niche were assessed. The cytokines TNF and IL-1 
that are suggested to reduce RBC survival were measured in plasma 















Fig. 2. Cancer-related anemia is caused by reduced RBC survival. (A) RBC survival of Ctrl and TB mice was assessed by measuring biotinylated Ter119+ RBCs throughout 
the study. (B) As a measure for RBC eryptosis propensity and susceptibility for erythrophagocytosis, phosphatidylserine externalization in Ter119+ RBCs was assessed by 
annexin V binding. (C) Representative picture and spleen mass quantification of Ctrl and TB mice 3.5 weeks after tumor cell inoculation. The ruler is in centimeters. 
(D) Representative flow cytometry plots of viable splenocytes and relative and absolute quantification of CD45+ cells taking into account the spleen mass and cell number. 
(E) Spleen cell composition with regard to leukocytes was analyzed by flow cytometry. NK, natural killer; DC, dendritic cell. (F) CD45−CD71+ cells were assessed. Groups (n = 5 
to 6 per group) were compared by two-tailed unpaired t tests with Welch’s correction and data are represented as means + SEM. Asterisks indicate differences between Ctrl 
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Fig. 3. Erythrophagocytosis is substantially elevated in TB mice. (A to D) Validation of the erythrophagocytosis assay using ImageStream®. Gates for PKH26low, PKH26med, 
and PKH26high were set according to the fluorescence of the PKH26-labeled RBCs (A), and phagocytes were analyzed accordingly (B). The rate of internalization of PKH26med 
(yellow) and PKH26high (red) cells was determined (a score higher than 0 is considered internalized), and the three different populations were visualized (D). Only PKH26high 
phagocytes show complete internalization and engulfment of entire RBCs. These plots and images are from the erythrophagocytosis experiment in which RBCs from TB 
mice were coincubated with healthy Ctrl splenocytes. (E) Representative flow cytometry plots with the gating strategy for F4/80highCD11blow red pulp macrophages, 
F4/80highCD11bhigh macrophages, and F4/80lowCD11bhigh monocytes/neutrophils (gated on CD45+ splenocytes). (F and G) PKH26 fluorescently labeled healthy RBCs were 
coincubated with splenocytes (spl) of either Ctrl or TB mice. Representative histograms of PKH26+ phagocytes including PKH26med and PKH26high (F) and the quantification 
of the percentage PKH26high cells representing phagocytes that engulfed complete RBCs (G). (H and I) PKH26 fluorescently labeled RBCs from Ctrl or TB mice were 
coincubated with healthy splenocytes. Representative histogram of PKH26+ F4/80lowCD11bhigh monocytes/neutrophils (H) and the quantification of the percentage 
PKH26high cells representing phagocytes that engulfed complete RBCs (I). Groups (n = 5 to 6 per group) were compared by two-tailed unpaired t tests with Welch’s correction 
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plasma of TB mice compared to Ctrl (Fig. 4A). Since the tumor 
induces major metabolic remodeling that could alter RBC environ-
ment, blood lactate levels and plasma levels of free fatty acids and 
triglycerides were determined and were shown to be substantially 
elevated (Fig. 4B). To obtain a global and unbiased overview of 
factors potentially promoting eryptosis, mass spectrometry–based 
metabolomics of the plasma was performed. This metabolomics 
analysis revealed a remarkable increase in many of the measured 
acylcarnitines and triglycerides in TB compared to Ctrl mice, visibly 
reflected in the opaque color of the plasma (Fig. 4, C to E). To test 
whether IL-1 or any of the metabolites could induce eryptosis, 
RBCs were isolated from healthy mice and treated with the identified 
candidates using concentrations similar to those measured in TB mice 
for 24 hours. Subsequently, eryptotic phosphatidylserine–exposing 
RBCs were assessed by annexin V binding (Fig. 4F). Notably, the 
tested triglycerides and acylcarnitines are only a selection of the 
large number of lipid species that was changed, and the candidates 
were selected on the basis of their abundance in Ctrl and TB mice. 
Lactate treatment reduced phosphatidylserine externalization as 
compared to vehicle treatment, suggesting that lactate is not likely 
to induce the eryptosis observed in vivo. In contrast, IL-1, the two 
acylcarnitines propionylcarnitine [AC(3:0)] and valerylcarnitine 
[AC(5:0)] as well as TG(54:4) increased phosphatidylserine external-
ization (Fig. 4F). Mechanistically, we could show that IL-1 receptor 1 
(IL1R1) is expressed on RBC and that IL-1 may promote phos-
phatidylserine externalization by activating caspase 3 (fig. S3) (32). 
Our data thus demonstrate that these metabolites and IL-1 promote 
eryptosis and might thereby contribute to the reduced RBC survival 
observed in TB mice.
The altered lipid profile in TB mice is caused by increased 
lipolysis in adipose tissue and reduced fatty acid  
oxidation in the liver
To shed light on the causes of the altered metabolic profile, we 
assessed body composition of Ctrl and TB mice using EchoMRI. 
In agreement with frequently reported cachexia during tumor 
development (33), fat mass was substantially reduced in TB mice 
(Fig. 5A). More specifically, epididymal and subcutaneous white 
adipose tissue (eWAT and sWAT, respectively) was considerably 
lower in TB mice (Fig. 5B). To test whether the tumor provoked 
metabolic remodeling in the liver in addition to elevated lipolysis in 
adipose tissue, expression levels of genes involved in fatty acid up-
take and oxidation were assessed in hepatic tissue. Fatty acid uptake 
into the cytosol does not seem to be altered, as expression of the 
fatty acid transporters CD36 was unchanged (Fig. 5C). In contrast, 
expression levels of carnitine palmitoyltransferase 1a (Cpt1a) and 
Cpt2 were lower in TB mice, suggesting that fatty acid uptake into 
the mitochondria is diminished. In addition to the reduced mito-
chondrial uptake, mRNA expression of genes involved in fatty acid 
oxidation and oxidative metabolism was also decreased in TB mice 
(Fig. 5C). Our findings suggest that the reduced oxidative metabo-
lism and fatty acid oxidation in the liver could contribute to the 
accumulation of acylcarnitines and triglycerides in plasma of TB 
mice and thereby affect RBC environment.
Exercise ameliorates tumor-associated anemia
As tumor-induced metabolic remodeling leading to substantial ele-
vation of acylcarnitines and triglycerides potentially contributes to 










































































Fig. 4. Tumor-induced metabolic remodeling and immune activation promotes 
eryptosis. (A and B) Levels of proinflammatory cytokines TNF and IL-1 (A) and 
blood lactate, free fatty acids, and triglycerides (B) were analyzed in plasma of Ctrl 
and TB mice 3.5 weeks after tumor inoculation. (C) Heatmap of acylcarnitines (ACs) 
and triglycerides (TGs) from the metabolomics analysis. (D) Representative picture 
of plasma of Ctrl and TB mice demonstrating the massive elevation of lipids. (E and 
F) The effects of candidates identified in metabolomics analysis (E) and IL-1 and 
lactate on eryptosis were tested by incubating healthy RBCs with the observed levels 
of IL-1 or the different metabolites. After 24 hours, eryptosis was measured by assess-
ing phosphatidylserine externalization via annexin V binding using flow cytometry 
(F). Groups (n = 5 to 7 per group) were compared by two-tailed unpaired t tests with 
Welch’s correction and data are represented as means + SEM. Data of in vitro eryptosis 
experiments consist of three independent experiments with three to four biological 
replicates. Asterisks indicate differences between Ctrl and TB/treated group. *P < 0.05, 
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whether normalizing the lipid profile by pharmacological or physio-
logical interventions could ameliorate the development of anemia. 
To address this question, we aimed at reducing plasma triglyceride 
levels by increasing fatty acid oxidation in the muscle or liver pharma-
cologically by treating mice with peroxisome proliferator–activated 
receptor / (PPAR) (GW501516) or PPAR (fenofibrate) agonists, 
respectively, or physiologically by endurance exercise. While the 
pharmacological interventions primarily target lipid metabolism, 
exercise obviously is multifactorial, with systemic benefits, including 
anti-inflammatory effects. The different interventions did not affect 
tumor growth, and tumor mass was similar between TB mice and 
TB mice treated with either PPAR or PPAR agonists or TB mice 
that performed exercise (fig. S4). Only TB mice and mice of the 
pharmacological intervention groups lost fat mass (Fig. 6A). Despite 
the elevated lipolysis, increasing fatty acid oxidation in the liver by 
the PPAR agonist fenofibrate substantially lowered triglyceride levels, 
which was not observed after the treatment with the PPAR agonist 
GW501516 (Fig. 6B). This suggests that enhancing fatty acid oxidation 
in the muscle alone was not sufficient to reduce triglyceride levels. 
Notably, the metabolic remodeling by exercise, including an increase 
in fatty acid oxidation, significantly lowered triglyceride levels compared 
to TB mice (Fig. 6B). To determine whether the normalization of the 
lipid profile could ameliorate RBC survival, eryptosis of RBCs was 
assessed. In fenofibrate- and GW501516-treated TB mice, annexin V 
binding was not elevated compared to Ctrl mice (Fig. 6C), suggesting 
that lowering triglyceride could reduce phosphatidylserine external-
ization, which is in line with our previous results showing that 
triglycerides promote eryptosis (Fig. 4F). However, the size of RBCs 
was unaffected by both pharmacological interventions (Fig.  6D), 
suggesting that the release of premature RBCs and thereby anemic 
stress is unaffected by the treatment. Accordingly, the development 
of anemia could not be blunted by fenofibrate nor GW501516 treat-
ment (Fig. 6E), indicating that eryptosis only contributes to a small 
extent to RBC elimination in the tumor context and that other factors 
account for the unfavorable RBC environment or activation of phago-
cytes. In contrast to the pharmacological approach, not only was 
phosphatidylserine externalization considerably lower in exercising 
TB mice (TB-ex) but also the increase in RBC size was normalized 
(Fig. 6, C and D). This effect likely resulted in a longer RBC survival 
and thereby attenuated development of anemia (Fig. 6E). Together, 
our data suggest that a targeted lowering of triglyceride levels is not 
sufficient to improve RBC life span, but that other factors that are 
affected by exercise are essential for RBC survival and thereby important 
to slow down the development of anemia.
Exercise might ameliorate tumor-associated anemia by 
reducing blood lactate and IL-1
As exercise does not only normalize the lipid profile in blood but 
also elicits a variety of systemic effects such as an anti-inflammatory 
response, we assessed IL-1 levels in the plasma. The significant 
elevation of IL-1 in TB mice was blunted by the training interven-
tion (Fig. 7A). Similarly, exercise could also prevent the rise in blood 
lactate in rest and after exercise (Fig. 7B), most likely due to a sub-
stantial elevation of the lactate importer monocarboxylate trans-
porter 1 (MCT1; encoded by Slc16a1) and lactate dehydrogenase B 
(Ldhb), converting lactate to pyruvate, in skeletal muscle (Fig. 7C 
and fig. S5A). Exercise also elicited effects on tumor lactate handling 
(fig. S5A). For example, tumors of TB-ex mice could contribute to 
the lower blood lactate levels, as these tumors express higher levels 











Fig. 5. Increased lipolysis and reduced fatty acid oxidation in the liver contributes to altered lipid profile in TB mice. (A) Body composition of Ctrl and TB mice 
assessed by EchoMRI at the end of the study. (B) Representative image depicting the fat loss and splenomegaly in TB mice. Quantification of eWAT and sWAT mass. 
(C) Relative mRNA expression levels of genes involved in fatty acid uptake and oxidation and oxidative capacity were measured in the liver of Ctrl and TB mice. Groups 
(n = 6 to 7 per group) were compared by two-tailed unpaired t tests with Welch’s correction and data are represented as means + SEM. Asterisks indicate differences 
between Ctrl and TB group. *P < 0.05, **P < 0.01, and ***P < 0.001. Cpt, Carnitine palmitoyltransferase; Acad, acyl-CoA dehydrogenases; Cs, citrate synthase; Sdh, succinate 
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MCT4 (encoded by Slc16a3). However, despite the reduction in 
circulating IL-1 in TB-ex animals, only minimal changes in the 
expression of a selection of cytokines and chemokines were found 
in the liver and tumor of TB and TB-ex animals (fig. S5, B and C).
As we have observed that IL-1 but not lactate promotes phos-
phatidylserine externalization on RBCs and thereby could contribute 
to reduced RBC survival, we next studied whether IL-1 or lactate 
could directly affect the phagocytic activity of splenocytes. First, we 
FACS (fluorescence-activated cell sorting)–sorted these phagocytes 
and measured gene expression to assess whether splenic phagocytes 
express lactate transporters and IL1R1 (Fig. 7D). The lactate importer 
MCT1 and exporter MCT4 are expressed by these cells, and, in TB 
mice, mRNA levels of both transporters are substantially elevated 
compared to Ctrl (Fig. 7D). In addition, these cells also express 
Il1r1, suggesting that lactate and IL-1 could affect cellular activity. 
Notably, phagocytes of TB mice express high levels of IL-1, which 
could contribute to the observed inflammatory profile and affect 
RBC survival (Fig. 7D). To investigate whether the normalization of 
IL-1 and lactate levels could affect RBC survival, we tested the effects 
of IL-1 and lactate on erythrophagocytosis in vitro. Splenocytes 
and PKH26-labeled RBCs of healthy Ctrl mice were treated with 
pathophysiological levels of IL-1, lactate, or medium only (un-
treated) for 1 hour. Subsequently, the cells were washed and pre-
treated, and untreated splenocytes were coincubated with untreated 
or pretreated RBCs, respectively. In the Ctrl condition, untreated 
splenocytes were coincubated with untreated RBCs. While pre-
treating RBC did not affect their susceptibility to be phagocytosed, 
pretreating splenocytes with either IL-1 or lactate lead to a higher 
number of highly PKH26-fluorescent F4/80highCD11bhigh and 
F4/80lowCD11bhigh cells that show internalization of entire RBCs 
(Fig. 7E and fig. S6). Our data therefore suggest that IL-1 and 
lactate increase the phagocytic activity of splenocytes to engulf healthy 
RBCs. Thus, exercise might ameliorate RBC life span by preventing 
the tumor-induced elevation in IL-1 and lactate level.
In line with the assumption of the partially preserved RBC life 
span, the spleen size of TB-ex mice was considerably smaller 
compared to that of TB mice (Fig. 8A). To verify whether these 
exercised mice experience less anemic stress, Epo expression in 
kidney and EPO plasma levels were determined (Fig. 8B). In line 
with the higher Hb levels in TB-ex mice (Fig. 6E), Epo expression in 
the kidney was lower compared to that of TB mice, which was sub-




































Fig. 6. Exercise ameliorates cancer-related anemia. To normalize lipid profile, fatty acid oxidation was increased in muscle or liver pharmacologically by treating mice 
with PPAR agonist GW501516 (GW) or PPAR agonist fenofibrate (feno), respectively, or physiologically by exercise (ex). (A) Body composition of Ctrl, TB, and TB mice of 
pharmacological or physiological intervention groups was assessed by EchoMRI at the end of the intervention. (B) Triglyceride levels were measured in plasma. (C) As a 
measure for eryptosis, phosphatidylserine externalization in Ter119+ RBCs was determined by annexin V binding using flow cytometry. (D) RBC size was assessed during 
blood count. (E) Hb levels were measured 3.5 weeks after tumor initiation. Differences between groups (n = 5 to 7 per group) were tested with one-way analyses of variance 
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EPO levels in plasma were increased in TB and TB-ex mice, levels in 
TB-ex animals were considerably reduced, suggesting that the overall 
anemic stress was decreased in the TB-ex group. Notably, the accu-
mulation of stage IV RBCs was rescued by exercise (Fig. 8C), which 
is also in line with the normalized RBC size (Fig. 6D) and demon-
strating the positive effects on RBC environment, maturation, and 
survival. Furthermore, in addition to the amelioration of anemia 
3.5 weeks after LLC inoculation, exercise delayed the onset of anemia 
(Fig. 8D). Last, we investigated whether these alterations resulted in 
enhanced physical performance. TB-ex mice were not only able to 
run longer than TB animals but there was also even a considerable 
elevation in endurance performance compared to healthy, untrained 
Ctrl mice (Fig. 8E). Collectively, our data reveal that exercise amelio-
rates the development of tumor-associated anemia by preserving 
a favorable environment for RBCs and thereby promoting RBC 
survival. This results in a substantial improvement in physical per-
formance that can have meaningful implications for patients with 
cancer suffering from anemia and fatigue.
DISCUSSION
A high number of patients with cancer suffer from anemia, with 
devastating effects on quality of life and survival, aggravated by a 
lack of efficacious, safe, and targeted therapeutic options. Therefore, 
a better understanding of the underlying mechanisms of tumor- 
associated anemia is fundamental to develop novel treatment strategies. 
In this study, we demonstrate that reduced RBC survival substan-
tially contributes to the development of anemia. We provide solid 
evidence that the tumor-induced immune response and metabolic 
remodeling result in an unfavorable environment for RBCs lead-
ing to premature elimination. We show that exercise is able to par-
tially normalize the systemic metabolic and immune profiles of TB 
mice and thereby ameliorates anemia and improves fatigability and 
endurance (Fig. 9). Thus, in cancer patients with pretreatment 
anemia, individuals in-between bouts of chemotherapy or bone 
marrow radiotherapy, or patients treated with immunotherapy or 
non–bone marrow radiotherapy, exercise, or interventions leveraging 
















Fig. 7. Exercise ameliorates anemia by its anti-inflammatory effects and the normalization of the metabolic profile. (A) IL-1 levels were assessed in plasma of Ctrl, 
TB, and TB-ex 3.5 weeks after tumor initiation. (B) Blood lactate levels in rest and immediately after exhausting exercise. (C) Relative mRNA expression levels of Ldha and 
Ldhb that convert pyruvate to lactate or lactate to pyruvate, respectively, were measured in muscle. (D) To assess the expression of lactate transporters MCT1 and MCT4 
and Il1r1, splenic phagocytes were FACS-sorted and mRNA levels were determined by qPCR. Expression of Il1b was also determined. (E) PKH26 fluorescently labeled 
healthy RBCs and healthy splenocytes were preincubated separately with pathophysiological levels of IL-1 (1 pg/ml) or lactate (10 mM) and then coincubated with either 
untreated splenocytes or untreated RBCs. These conditions were compared to the Ctrl condition in which untreated splenocytes were coincubated with untreated RBCs. 
Quantification of the percentage PKH26high cells that engulfed complete RBCs is shown. Differences between groups (n = 5 to 7 per group) were tested with one-way 
ANOVAs followed by Tukey’s post hoc analysis, and data are represented as means + SEM. Data of in vitro erythrophagocytosis experiments consist of three independent 
experiments with three to four biological replicates, and Ctrl and treatment groups were compared by two-tailed unpaired t tests with Welch’s correction. If not indicated 
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mitigating RBC destruction, thereby complementing EPO-based stan-
dard therapy for treatment-caused anemia that boosts erythropoi-
esis. Notably, patients suffering from different degrees of anemia, 
even only mild forms, might profit from these therapies, as also mild 
anemia can lead to fatigue and reduced quality of life (34).
Even in the absence of metastases, primary tumors elicit a massive, 
multifactorial remodeling of systemic immune function and meta-
bolic profiles (35). For example, our metabolomics interrogation 
revealed a comprehensive alteration in circulating lipids, closely 
correlated to tumor-induced lipolysis in adipose tissue and a reduc-
tion in fatty acid oxidation in the liver. Intriguingly, we identified 
individual metabolites and cytokines—e.g., specific triglyceride 
species, lactate, or IL-1—that affect RBC levels by modulating 
eryptosis or phagocytosis. These and other metabolites and cytokines 
most likely synergize, potentially with reactive oxygen species and 
other compounds, to collectively reduce RBC levels and trigger 
tumor-associated anemia (11, 22, 24, 36). The complexity of these 
interactions was underlined by the inability of narrow pharmaco-
logical interventions to rectify this pathological process, e.g., those 
aimed at lowering circulating triglycerides by activating PPAR or 
PPAR. These experiments furthermore revealed that mitigation of 
eryptosis in the absence of additional benefits on erythrophagocytosis 
is insufficient to elevate Hb in cancer. In stark contrast, endurance 
training, which elicits multifactorial and multisystemic effects, was 
much more potent in reducing anemia and boosting endurance 
in TB animals.
Current therapies for cancer-related anemia aim at increasing 
RBC production, which is most notably impaired in treatment- 
induced anemia (7). We now provide strong evidence in our primary 
tumor model—where tumor anemia develops in parallel to tumor 
growth—that the systemic physiological anemia response is pre-
served as reflected by the dynamic EPO regulation and production 
and the ensuing erythropoietic process. EPO production is highly ele-
vated in TB mice and associated with extramedullary erythropoiesis. 
The incomplete maturation and premature release of RBC precursors 
would indicate that a further acceleration of erythropoiesis by phar-
macological means could be detrimental. Furthermore, as a reserve 
erythropoietic organ, we and others show a remarkable increase in 
spleen size that is mainly attributed to the augmentation in eryth-
roid Ter119+ cells, while the proportion B cells and T cells decrease 
with tumor progression (27, 37). These Ter119+ cells in the spleen 






































Fig. 8. Exercise delays the onset of anemia and substantially elevates performance. (A) Representative image and quantified spleen mass of Ctrl, TB, and TB-ex 
mice 3.5 weeks after tumor cell inoculation. The ruler is in centimeters. (B) EPO levels in kidney and plasma. (C) Maturation of Ter119+ cells in blood were analyzed 
according to their size and CD44 expression as shown in the representative flow cytometry plots and quantified in the bar graph. (D) Time course of Hb levels in Ctrl, TB, 
and TB-ex mice throughout the study. (E) The effects of the intervention on maximal performance tested on a motorized treadmill represented as a Kaplan-Meier Curve 
or bar graph showing maximal distance covered by the mice. Kaplan-Meier curves were compared with a log-rank test, differences between groups (n = 5 to 7 per group) 
were tested with one-way ANOVAs followed by Tukey’s post hoc analysis, and data are represented as means + SEM. *P < 0.05, **P < 0.01, and ***P < 0.001. In (D), aster-
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but also secrete factors that are associated with tumor progression 
and reduced survival (37). Therefore, instead of targeting produc-
tion, tumor anemia therapies should blunt the elevated destruction 
of RBCs on several levels.
Our findings point toward a change in the RBC environment 
leading to intrinsic alterations that trigger eryptosis and consequently 
removal. To maintain RBC integrity, hepatic and splenic phagocytes 
rapidly eliminate stressed RBCs (30, 38). In addition, tumor-induced 
systemic changes also alter the activation state of splenic macro-
phages, e.g., as indicated by the greater propensity of such macro-
phages to phagocytose RBCs derived from healthy animals. 
Collectively, the systemic environment evoked by the tumor thus 
results in compromised RBCs marked for removal and activation of 
macrophages to engulf RBCs even in the absence of stress markers 
including externalized phosphatidylserine and abnormal mean cor-
puscular volume (MCV). In light of the minor effect of mitigating 
eryptosis, MCV might be a more relevant and accessible parameter 
to determine therapeutic efficacy in tumor-associated anemia than 
phosphatidylserine. High MCV predicts poor overall survival of pa-
tients with cancer (39, 40), which further highlights the therapeutic 
potential of exercise to enhance survival.
We now describe lactate and IL-1 as two examples of circulating 
factors that are altered in TB mice and that affect RBC and macro-
phage behavior. A normalization of the levels of these and other 
systemic metabolites, cytokines, and hormones could therefore be 
leveraged to clinically address cancer anemia in patients. For example, 
several IL-1 inhibitors are already Food and Drug Administration–
approved (41), and treating participants with a history of myocardial 
infarction with the monoclonal anti–IL-1 antibody canakinumab 
reduced the incidence of anemia during the 5-year study period 
(42). Although a phase 1 clinical trial treating breast cancer patients 
with the IL-1 receptor antagonist anakinra has been conducted 
(NCT01802970), results on anemia have not been published so far. 
Therefore, it is still ill-defined whether blocking IL-1 in patients 
with cancer ameliorates anemia. Until efficacious and safe pharma-
cological interventions are found, exercise-based approaches could 
provide significant relief of anemia and the ensuing pathologies. In 
our studies, endurance training normalized metabolic parameters 
and inflammation in TB animals and elevated Hb levels. Moreover, 
exercised animals exhibited several hallmarks of reduced anemic 
stress, including lower EPO production and premature release 
of RBCs progenitors and a blunted splenomegaly and thus 
extramedullary erythropoiesis. This normalization in spleen size 
also lowers the abundance of F4/80highCD11blow RPMs and 
F4/80highCD11bhigh macrophages and thereby suppresses the total 
erythrophagocytic potential of the spleen. A limitation of this study 
is, however, that this was so far only shown in one tumor model, 
and it would be important to replicate these finding with other 
types of tumors. In addition, the dissection of exercise-induced 
benefits in a metastatic tumor model and an experimental group 
receiving treatment would further improve our understanding on 
the exercise effects on cancer-related anemia in general. Last, the 
translational implementation of such interventions to patients in 
the clinic will also be subject for future research.
Notably, the substantial increase in performance in TB-ex mice 
highlights the importance of physical activity in the treatment of 
fatigue that could have a major impact on quality of life. The multi-
factorial effects of exercise can be essential in the treatment of patients 
with cancer regarding quality of life, cancer recurrence, and survival 
(43–45). Even during ongoing cancer-reductive therapy, exercise 
Fig. 9. Exercise mitigates tumor-associated anemia. Graphical illustration of tumor-induced inflammatory and metabolic remodeling that affects RBC survival by acti-
vating splenic phagocytes and increasing the susceptibility of RBCs to be eliminated, which eventually results in anemia and increased fatiguability. Exercise can partially 
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could significantly improve physical functionality and fatigue and 
reduce treatment-induced adverse effects that all contributed to 
increase quality of life (46, 47). In preclinical models, exercise could 
even elevate chemotherapy efficacy (48). However, the experienced 
fatigue, the time-consuming therapies and nausea, physical im-
pairments, a catabolic state, and low-energy substrate levels often 
impede the engagement in exercise training in patients with cancer. 
Training interventions thus have to be guided, supervised, and indi-
vidually adjusted to comorbidities and symptoms (49). Furthermore, 
it is instrumental to understand the underlying systemic, cellular, and 
molecular mechanisms to design treatments that could promote 
exercise effects and/or facilitate exercise-based therapies. Neverthe-
less, if patients are able to perform exercise, then endurance training 
is a potent, safe, and cost-effective therapeutic intervention to allevi-
ate cancer-related symptoms such as reduced physical functionality 
and fatigue and possibly tumor-associated anemia. This could im-




For this study, male C57BL/6J mice were kept under standard con-
ditions with a 12-hour light/12-hour dark cycle and food and water 
ad libitum. To study the effects of the tumor and interventions on 
anemia, we used a randomized study design. At the age of 16 to 
18 weeks, tumor cells were injected into the flank of the mice and 
25 days (3.5 weeks) after tumor cell inoculation, mice were sacrificed. 
One of the pharmacological interventions (GW501516) started con-
comitant with tumor injection, while treatment with fenofibrate 
started 10 days after injection. The exercise intervention started 
4 weeks before tumor cell inoculation. To exclude any acute effects 
of the intervention, mice assigned to pharmacological or exercise 
intervention were sacrificed 24 or 48 hours after the last injection or 
exercise bout, respectively. On the last day, body composition of the 
mice was assessed with an EchoMRI (Medical Systems). During the 
dissection, blood was collected from the vena cava in Li-heparin– 
and EDTA-coated tubes (Sarstedt), and plasma was stored for further 
analysis. Furthermore, tumor, spleen, and different WAT depots 
were removed and weighted. In addition, bone marrow, spleen, kidney, 
liver, and muscle tissues were collected and either immediately pro-
cessed and analyzed by flow cytometry or frozen in liquid nitrogen 
for later analyses. All experiments were approved by the Kantonales 
Veterinäramt Basel-Stadt and followed the Swiss guidelines for 
animal experimentation and care.
Tumor model
To study tumor-associated anemia, we chose a well-established pri-
mary tumor model that is known to develop robust anemia (50) and 
that is unlikely to metastasize within the 3.5-week study period. In 
addition, anemia induced by tumors originating from LLC show 
characteristics observed in anemic patients with cancer (27). To in-
duce tumors, LLC cells were subcutaneously injected into the flank. 
LLC cells obtained from the American Type Culture Collection 
(ATCC CRL-1642) were first proliferated for 5 days in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% fetal bovine 
serum (FBS). Then, cells were resuspended in phosphate-buffered 
saline (PBS) at a concentration of 1 × 106 cells/ml of which 100 l 
was injected (1 × 105 cells). Ctrl animals were injected with 100 l of 
PBS. During this procedure, mice were anesthetized using inhalation 
anesthesia. Mice that did not develop a palpable tumor after 2 weeks 
usually never developed a tumor and were therefore excluded from 
the study (n = 3). Postmortem, mice were analyzed for the occur-
rence of metastases.
Pharmacological intervention
During the pharmacological intervention, aimed at increasing fatty 
acid oxidation in muscle or liver, mice were intraperitoneally injected 
with the PPAR agonist GW501516 (AdipoGen Life Sciences) or 
the PPAR agonist fenofibrate (Sigma-Aldrich). GW501516 was 
dissolved in 2.5% dimethyl sulfoxide (DMSO) and saline and injected 
with a final concentration of 5 mg/kg body weight (injection volume 
was 5 l/g body weight). Fenofibrate was dissolved in corn oil 
(Sigma-Aldrich), and a final concentration of 50 mg/kg body weight 
in a total volume of 50 l was injected. Ctrl mice received vehicle 
injections of either 2.5% DMSO in saline or 50 l of corn oil.
Exercise intervention
To maximize the time and effects of the exercise intervention and to 
prime the immune system as shown previously (46), TB mice sub-
jected to the exercise intervention group (TB-ex) received running 
wheels (Columbus Instruments) 4 weeks before tumor initiation. 
Mice had free-running wheel access until 48 hours before the termina-
tion of the experiment, and voluntary running activity was recorded 
throughout the experimental period. In addition to free-running 
wheel access, mice were trained on a motor-driven treadmill 
(Columbus Instruments) 5 days/week for 1 hour. The training 
started 3 weeks before LLC injection, and the last training was per-
formed 48 hours before the termination of the experiment. The 
training was performed at an inclination of 5°, and the velocity was 
progressively increased up to 2 weeks after inoculation (to 20 m/min) 
and was thereafter slightly reduced because of disease progression. 
Mice that did not run on the treadmill and covered less than 1 km/day 
in the running wheels were excluded from the study. Maximal per-
formance was tested half a week before the end of the experiment. 
Mice that have not ran on a treadmill before were acclimatized to 
treadmill running for 2 days. The maximal performance test was 
executed at an inclination of 5° and started with 5 min at 5 m/min, 
followed by 5 min at 8 m/min and 15 min at 10 m/min. Subsequently, 
velocity was increased every 15 min by 2 m/min until exhaustion. 
Exhaustion was defined as the time point at which mice could not 
further keep up with the speed. An electrical grid at the end of the 
treadmill was used as motivational stimulus.
Longitudinal blood measurements
Hb levels were assessed by performing a blood count (ADVIA 2120, 
Siemens) or using a Hb analyzer (EKF Diagnostics). Blood lactate 
was measured with a lactate meter (Nova Biomedical). To trace RBCs 
and thereby assess RBC life span, EZ-Link Sulfo-NHS-Biotin 
(100 mg/kg body weight; Thermo Fisher Scientific) was intravenously 
injected 3 days before tumor cell inoculation (51). Every 3 to 7 days, 
2 l of blood were stained with Ter119-phycoerythrin (PE) (1:200; 
clone TER-119, BioLegend) and streptavidin-allophycocyanin (APC) 
(1:200; BioLegend) and analyzed on BD FACSCanto II.
Plasma analysis
Cytokine levels of TNF and IL-1 were measured in plasma using 
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Scale Discovery). Free fatty acids in plasma were assesses with the 
Free Fatty Acid Quantitation Kit MAK044 (Sigma-Aldrich), tri-
glycerides using the cobas c 111 analyzer (Roche Diagnostics AG), 
and EPO levels with the mouse EPO PicoKine ELISA Kit (Boster 
Biological Technology). All analyses were performed according to 
the manufacturers’ protocols.
A global overview of acylcarnitine and triglyceride levels in plasma 
was obtained by targeted mass spectrometry–based metabolomics 
using the AbsoluteIDQ p400 HR Kit (Biocrates Life Sciences AG, 
Innsbruck, Austria) and performed by Biocrates according to the 
manufacturer’s instructions as described previously (52). Data were 
analyzed with the Biocrates MetIDQ software.
Single-cell suspensions
Single-cell suspensions of the bone marrow and spleen were pre-
pared immediately after the dissection. Cell suspension of the bone 
marrow was obtained by mechanical dissociation of the tibia using 
a mortar and subsequently filtering through a 70-m cell strainer 
(Falcon). The spleen was mashed through a 70-m cell strainer. To 
remove RBCs from the spleen cell suspension used for the erythro-
phagocytosis assay, RBCs were lysed in ACK lysing buffer (Gibco).
Erythrophagocytosis
For the erythrophagocytosis assay, blood was collected in EDTA- 
coated tubes and centrifuged for 10 min at 400g. After removing the 
buffy coat, RBCs were washed with PBS. To fluorescently label RBCs, 
the PKH26 Red Fluorescent Cell Linker Kit (Sigma-Aldrich) was 
used. Ten to fifty microliters of packed RBCs were resuspended in 
100 to 500 l of diluent C and 100 to 500 l of diluent C containing 
4 M PKH26 dye and incubated for 5 min protected from light. The 
reaction was stopped by incubation with the equal volume of FBS 
for 1 min. RBCs were washed twice with PBS containing 5% FBS. To 
assess erythrophagocytosis, 4 × 106 splenocytes were mixed with 
2.5 l of packed PKH26-labeled RBCs and coincubated in DMEM con-
taining 10% FBS for 1 hour at 37°C in a humidified 5% CO2 incubator. 
After 1 hour, remaining RBCs were removed using ACK lysing 
buffer. Following this, cells were prepared for flow cytometry 
(see below).
In vitro experiments
To test the eryptotic potential of the identified candidates, blood was 
collected in Li-heparin–coated tubes and centrifuged for 20 min at 
120g as previously described (53). Supernatant was discarded and 
RBCs were washed in Ringer solution containing 125 mM NaCl, 
5 mM KCl, 1 mM MgSO4, 32 mM N-2-hydroxyethylpiperazine-N- 
2-ethanesulfonic acid (Hepes), 5 mM glucose, and 1 mM CaCl2 
(pH 7.4). RBCs were incubated in Ringer solution containing recom-
binant mouse IL-1 (1 pg/ml; BioLegend), 10 mM sodium l-lactate 
(Sigma-Aldrich), 2 M propionylcarnitine (Sigma-Aldrich), 1 M 
valerylcarnitine (MedChemExpress), 600 M TG(54:4) (Sigma- 
Aldrich), or vehicle Ctrl at a hematocrit of 0.4% for 24 hours at 37°C 
in a humidified 5% CO2 incubator. After 24 hours, RBCs were 
washed and stained with annexin V–fluorescein isothiocyanate 
(FITC; 1:100; BioLegend) and measured on BD FACSCanto II as 
described below.
To investigate the effects of IL-1 and lactate on erythrophago-
cytosis, splenocytes of healthy Ctrl mice were isolated and RBCs were 
labeled with PKH26 as described in the previous sections. Spleno-
cytes and labeled RBCs were preincubated in DMEM containing 
10% FBS alone or with additional recombinant mouse IL-1 (1 pg/ml) 
or sodium l-lactate (10 mM) for 1 hour. After 1 hour, cells were 
washed and 4 × 106 pretreated splenocytes were coincubated with 
2.5 l of untreated RBCs and 4 × 106 untreated splenocytes with 
2.5 l of pretreated and untreated RBCs. After incubating for 1 hour, 
remaining RBCs were lysed using ACK lysing buffer and prepared 
for flow cytometry or FACS sorting as describe below.
Flow cytometry
To assess RBC maturation (54, 55), bone marrow and spleen cells 
were treated with TruStain FcX (1:200; clone 93, BioLegend) and 
stained in PBS containing 5% FBS using the following antibodies: 
CD71-FITC (1:200; clone RI7217, BioLegend), Ter119-PE (1:200; 
clone TER-119, BioLegend), CD44-PE/Cy7 (1:400; clone IM7, 
BioLegend), and SYTOX Blue dead cell stain (1:5000; Invitrogen). 
Blood was first stained with Ter119-PE and CD44-PE/Cy7 and sub-
sequently with annexin V–FITC (1:100; BioLegend) using annexin V 
binding buffer (BioLegend) to assess phosphatidylserine external-
ization. Cells were analyzed on BD FACSCanto II. To analyze DNA 
content in RBC, blood was first stained in PBS containing 5% FBS 
with CD71-FITC (1:200; clone RI7217, BioLegend), Ter119-PE 
(1:200; clone TER-119, BioLegend), and subsequently with DRAQ5 
(1:1000; BioLegend). Cells were analyzed on BD LSRFortessa. 
Splenocytes from the erythrophagocytosis assays were treated with 
TruStain FcX (1:200) and stained in PBS containing 5% FBS using 
the following antibodies: CD45-APC/Cy7 (1:200; clone 30-F11, 
BioLegend), CD11b-FITC (1:200; clone M1/70, BioLegend), F4/80-
APC (1:100; clone BM8, BioLegend), and SYTOX Blue dead cell 
stain (1:5000; Invitrogen). Cells were analyzed on BD LSRFortessa 
(a subset was measured on ImageStreamX® Mark II as described 
below). To determine the composition of the spleen, splenocytes 
(both prior and after performing RBC lysis) were treated with 
TruStain FcX (1:200; clone 93, BioLegend) and stained in PBS con-
taining 5% FBS using the following antibodies: CD45-APC/Cy7 
(1:200; clone 30-F11, BioLegend), CD71-FITC (1:200; clone RI7217, 
BioLegend), Ter119-PE (1:200; clone TER-119, BioLegend), and 
SYTOX Blue dead cell stain (1:5000; Invitrogen). Cells were analyzed 
on BD LSRFortessa. For the assessment of the CD45+ population in 
the spleen, splenocytes were treated with TruStain FcX (1:200; clone 
93, BioLegend) and stained in PBS using the following antibodies: 
CD11b-FITC (1:100: clone M1/70, BioLegend), B220-BV421 (1:100; 
clone RA3-6B2; BioLegend), CD4-BV510 (1:100; clone RM4-5, 
BioLegend), CD19-BV605 (1:100; clone 6D5, BioLegend), CD3-BV711 
(1:100; clone 17A2, BioLegend), CD8-BV785 (1:100; clone 53-6.7, 
BioLegend), F4/80-PE (1:100; clone BM8, BioLegend), CD11c-PE/
Cy7 (1:100; clone N418, BioLegend), NK1.1-APC (1:80; clone PK136, 
BioLegend), CD45-AF700 (1:200; clone 30-F11, BioLegend), and 
viability-APC/Cy7 (1:2000; Invitrogen). Cells were analyzed on 
BD LSRFortessa. Data analysis was performed using the FlowJo 
V10 software.
FACS sorting
Cell suspension of splenocytes was treated with TruStain FcX 
(1:200; clone 93, BioLegend) and stained in PBS containing 5% FBS 
using the following antibodies: CD45-APC/Cy7 (1:200; clone 30-F11, 
BioLegend), CD11b-PE/Cy7 (1:100; clone M1/70, BioLegend), 
BV605-F4/80 (1:100; clone BM8, BioLegend), and SYTOX Blue 
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Imaging flow cytometry
Samples were prepared as described for the other erythrophagocytosis 
experiments (see the “In vitro experiments” and “Flow cytometry” 
sections). All samples were acquired using a 12-channel Amnis® brand 
ImageStreamX® Mark II (Luminex, Austin, Texas) imaging flow 
cytometer equipped with four excitation lasers [120 mW (405 nm), 
200 mW (488 nm), 200 mW (561 nm), and 150 mW (642 nm)] and 
a MultiMag with three objectives lenses (×20, ×40, and ×60 magni-
fication). Samples were acquired at ×60 magnification, and the 
excitation lasers (405, 488, and 642 nm) were used at full power. 
Single-color compensation controls for CD11b-FITC, PKH26, 
SYTOX Blue dead cell stain-PB, F4/80-APC, and CD45-APC/Cy7 
were also acquired using the integrated software INSPIRE® (Luminex) 
for data collection.
Image analysis was performed using image-based algorithms in 
the ImageStream Data Exploration and Analysis Software (IDEAS® 
6.2.187, Luminex). Typical files contained imagery for 50,000 to 
100,000 cells. The analysis was restricted to single cells in best focus. 
Single cells were identified by their intermediate size (area) and 
high aspect ratio (minor axis divided by the major axis) in compar-
ison to debris (small area and a range of aspect ratios depending on 
the shape of the debris) and doublets (large area and small aspect 
ratio). Out-of-focus events were excluded by using the feature 
bright-field gradient RMS, a measurement of image contrast. Only 
living cells negative for the LIVE/DEAD marker were selected to 
quantify the internalization of erythrocytes. To calculate the internal-
ization, a mask was designed that identifies the inside of the cells. 
The tight object mask of the CD45 image was used to define the area 
corresponding to the cell. This mask was eroded by 2 pixels to ex-
clude the cell membrane. The intracellular mask was then used to 
calculate the Internalization feature applied to the PKH26 channel. 
Internalization is defined as the ratio of the PKH26 intensity inside 
the cell (the intracellular mask) to the intensity of the entire cell. 
This ratio is log-transformed to increase the dynamic range (−inf to 
+inf). Internalized cells typically have positive scores, while cells 
with little internalization have negative scores.
To quantify the different RBC morphologies in the tumor and 
Ctrl samples, two super-features were generated using the Machine 
Learning (ML) module for IDEAS® 6.3. After manual selection of the 
“truth” populations, the ML algorithm calculates the super-feature 
that maximally separates each truth population from the others. 
This classifier is based on user-defined and/or ML-generated single 
features, which are ranked and combined by a Linear Discriminant 
Analysis. The two output classifiers (for stomatocyte-like and 
discocyte-like RBCs) contain a series of differentially weighted features 
targeted to the corresponding phenotype and are plotted in a two- 
dimensional scatter plot against each other. Events with values greater 
than zero are images that are best represented by the specific classi-
fier. The analysis was restricted to CD45−PKH26+ singles cells.
RNA extraction and semi quantitative reverse transcription 
polymerase chain reaction analysis
Gene expression levels were determined in liver, kidney, spleen, and 
muscle tissues. Tissue was homogenized in 1 ml of TRIzol agent 
(Sigma-Aldrich) using FastPrep tubes (MP Biomedicals), and RNA 
was isolated according to the manufacturer’s instructions. FACS- 
sorted phagocytes were pelleted by centrifugation for 5 min at 400g 
and disrupted in 350 l of RLT buffer (Qiagen RNeasy Mini Kit) 
using a 30-gauge needle and syringe. RNA isolation was further 
performed according to the manufacturer’s protocol. RNA concen-
tration and quality were determined on the NanoDrop OneC spectro-
photometer (Thermo Fisher Scientific). Subsequently, 1 g of RNA 
was treated with deoxyribonuclease I (Invitrogen) and reverse- 
transcribed using the High Capacity cDNA RT Kit (Applied Biosystems). 
Because of limited material of FACS-sorted phagocytes, only 300 ng 
of RNA was reverse-transcribed using the High Capacity cDNA 
RT Kit (Applied Biosystems). Gene expression was measured on 
QuantStudio 5 Real-Time PCR System (Applied Biosystems) using 
Fast SYBR Green Master Mix (Applied Biosystems). Primer sequences 
are listed in Table 1. Values were normalized to the housekeeping 
gene [TATA box–binding protein (Tbp) or 18S], and gene expression 
was expressed relative to the Ctrl group using the 2-Ct method (or 
relative to the TB group in case of tumor tissue).
Protein isolation
To isolate proteins from RBCs, they were washed twice in PBS and 
centrifuged at 400g for 5 min followed by lysis in a 10-fold volume 
of ACK lysis buffer supplemented with protease and phosphatase 
inhibitor. Cellular debris was removed by centrifugation at 13,000g 
for 10 min, and protein concentration was determined in the super-
natant using Bradford assay.
For proteins isolation from dissected pancreas, 30 mg of pancreas 
tissue was disrupted within protein lysis buffer (0.1% SDS, 1%NP-40, 
5% glycerol, 1 mM EDTA, 150 mM NaCl, and 50 mM tris) using a 
tissue lyser. After 30-min incubation, lysate was centrifuged for at 
13,000g for 10 min to remove tissue debris. Protein concentration 
was determined using Bradford assay.
Immunoprecipitation
For the detection of IL1RI in RBCs, 4000 g of RBC protein was 
incubated for 16 hours with 1:100 diluted goat anti-mouse IL1RI 
antibody (no. AF771, R&D Systems) in 400 l of protein lysis buffer 
under rotation. Subsequently, antibodies were captured by incu-
bation with 50 l of Protein A/G PLUS-Agarose (no. sc-2003, Santa 
Cruz Biotechnology) for 2 hours. Beads were washed consecutively 
with low-salt buffer [50 mM tris-HCl, 150 mM NaCl, 2 mM EDTA, 
and 1% Triton X-100 (pH 7.5)], high-salt buffer [50 mM tris-HCl, 
500 mM NaCl, 2 mM EDTA, and 1% Triton X-100 (pH 7.5)], and 
LiCl wash buffer [50 tris-HCl, 250 mM LiCl, 2 mM EDTA, and 1% 
Triton X-100 (pH 7.5)] with centrifugation at 1000g for 30 s in be-
tween. Last, beads were incubated in 1× Laemmli buffer for 5 min at 
95°C before Western blotting.
Western blotting
Protein lysates from RBCs were mixed with an equal volume of 
twofold protein lysis buffer (0.2% SDS, 2% NP-40, 10% glycerol, 
2 mM EDTA, 300 mM NaCl, and 100 mM tris) before use. For 
Western blotting, 200 g of RBC protein or 30 g of pancreas pro-
tein was prepared with Laemmli buffer, incubated at 95°C for 5 min, 
and loaded onto a 15% polyacrylamide gel. Separated proteins were 
blotted onto membranes during 1 hour at 100 V. Subsequently, 
membranes were blocked against unspecific binding with 5% dry 
milk powder in TBS-T for 2 hours, followed by primary antibody 
incubation for 16 hours using either 1:500 diluted rabbit anti-mouse 
caspase 3 antibody (no. 9662, Cell Signaling Technology) or 1:1000 
diluted goat anti-mouse IL1RI antibody (no. AF771, R&D Systems) 
in 1% bovine serum albumin (BSA)/TBS-T (Tris-buffered saline 











Furrer et al., Sci. Adv. 2021; 7 : eabi4852     8 September 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
15 of 17
10 min each, second antibody incubation using 1:10,000 dilutions of 
either swine anti-rabbit immunoglobulin G (IgG)/horseradish peroxidase 
(HRP) (no. P0399, Dako) or rabbit anti-goat IgG/HRP (no. P0449, 
Dako) in 1% BSA/TBS-T was performed. Protein bands were detected 
and visualized using SuperSignal West Femto substrate (no. 34094, 
Thermo Fisher Scientific) and a Vilber Fusion FX detector.
Statistical analyses
Statistical analyses were performed on GraphPad Prism 8. To ex-
clude mice that showed an abnormal response to the tumor cell in-
jection, a stringent outlier test ROUT (Q set at 0.1%) for Hb levels 
was performed that only detected definite outliers. Of the 41 TB mice, 
one had to be excluded. Differences between two groups were tested 
with two-tailed unpaired t tests with Welch’s correction. One-way 
analyses of variance (ANOVAs) followed by Tukey’s post hoc 
analysis were performed to test for differences between three groups. 
Kaplan-Meier curves were compared with a log-rank test. Differ-
ences with P < 0.05 were considered statistically significant. Values 
are presented as means + SEM, and n values are provided in the 
figure legend.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.abi4852
View/request a protocol for this paper from Bio-protocol.
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